DelveInsight’s, “Allergic Rhinitis Pipeline Insight 2023” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Allergic Rhinitis pipeline landscape. It covers the Allergic Rhinitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Allergic Rhinitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Allergic Rhinitis Pipeline Report

• DelveInsight’s Allergic Rhinitis pipeline report depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Allergic Rhinitis treatment.
• The leading companies working in the Allergic Rhinitis Market include Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma, and others.
• Promising Allergic Rhinitis Pipeline Therapies in the various stages of development include Levocetirizine, INI-2004, BLX-028914, Nasapaque Nasal Solution, MK-8237, and others.
• September 2023: Abdi Ibrahim Ilac San. ve Tic A.S. announced a study of phase 3 clinical trials for AI201901 and Azelastine Hydrochloride. This is a prospective, national, randomized, multicenter, parallel group, Phase III study that evaluates the effects of AI201901 in Allergic Rhinitis patients, where they will spray twice a day against azelastine into both nostrils during a 28-day follow-up period.
• September 2023: Synmosa Biopharma Corp. announced a study of phase 2 clinical trials for Dymista™ and azelastine/fluticasone 137/50 mcg nasal spray. The purpose of this study is to evaluate the efficacy and safety of Azelastine HCl-Fluticasone propionate Nasal Spray 137-50 mcg/spray compared to Dymista™ in patients with perennial allergic rhinitis.

 

Request a sample and discover the recent advances in Allergic Rhinitis Treatment Drugs @ Allergic Rhinitis Pipeline Report

 

In the Allergic Rhinitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic Rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Allergic Rhinitis Overview

Allergic rhinitis (AR) is an atopic disease presenting with symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response that is against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase.

 

Find out more about Allergic Rhinitis Therapeutics Assessment @ Allergic Rhinitis Preclinical and Discovery Stage Products

 

Allergic Rhinitis Emerging Drugs Profile

• REGN5713-5714-5715: Regeneron Pharmaceuticals
• MM09-MG01: Immunotek

 

Allergic Rhinitis Pipeline Therapeutics Assessment

There are approx. 35+ key companies which are developing the Allergic Rhinitis therapies. The Allergic Rhinitis companies which have their Allergic Rhinitis drug candidates in the mid to advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals.

 

Learn more about the emerging Allergic Rhinitis Pipeline Therapies @ Allergic Rhinitis Clinical Trials Assessment

 

Scope of the Allergic Rhinitis Pipeline Report

• Coverage- Global
• Allergic Rhinitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Allergic Rhinitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Allergic Rhinitis Companies- Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma, and others.
• Allergic Rhinitis Pipeline Therapies- Levocetirizine, INI-2004, BLX-028914, Nasapaque Nasal Solution, MK-8237, and others.

 

Dive deep into rich insights for new drugs for Allergic Rhinitis Treatment, Visit @ Allergic Rhinitis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Allergic Rhinitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. REGN5713-5714-5715: Regeneron Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. IRL201104: Revolo Biotherapeutics
11. Drug profiles in the detailed report…..
12. Pre-clinical and Discovery Stage Products
13. Drug profiles in the detailed report…..
14. Inactive Products
15. Allergic Rhinitis Key Companies
16. Allergic Rhinitis Key Products
17. Allergic Rhinitis- Unmet Needs
18. Allergic Rhinitis- Market Drivers and Barriers
19. Allergic Rhinitis- Future Perspectives and Conclusion
20. Allergic Rhinitis Analyst Views
21. Allergic Rhinitis Key Companies
22. Appendix

 

For further information on the Allergic Rhinitis Pipeline therapeutics, reach out to Allergic Rhinitis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking